Baltimore-based Osiris Therapeutics has pocketed $50 million from a Swiss investment firm. That's more than twice the $20 million the biotech had hoped to raise in the round. Zurich-based Friedli Corporate Finance, which is owned by Osiris' chairman of the board, led the round. Osiris has been hot on the trail of a new adult stem cell treatment to regenerate diseased or damaged tissue. It expects to have its first commercial offering in 2006.

- read this story [1] from the Baltimore Sun